Stockscreener 앱 받기
1.42
9.23%
0.12
시간 외 거래:
1.49
0.07
+4.93%
전일 마감가:
$1.30
열려 있는:
$1.3
하루 거래량:
2.07M
Relative Volume:
1.76
시가총액:
$88.42M
수익:
-
순이익/손실:
$-73.79M
주가수익비율:
-0.7717
EPS:
-1.84
순현금흐름:
$-77.44M
1주 성능:
+23.48%
1개월 성능:
-66.35%
6개월 성능:
+24.56%
1년 성능:
-18.39%
1일 변동 폭
$1.285
$1.52
1주일 범위
$1.13
$1.52
52주 변동 폭
$0.8332
$5.55
Pyxis Oncology Inc Stock (PYXS) Company Profile
명칭
Pyxis Oncology Inc
전화
(617) 221-9059
주소
321 HARRISON AVENUE, BOSTON
PYXS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PYXS
Pyxis Oncology Inc
|
1.42 | 80.94M | 0 | -73.79M | -77.44M | -1.84 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.15 | 118.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
812.27 | 81.61B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
422.50 | 53.69B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.94 | 49.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.00 | 37.34B | 447.02M | -1.18B | -906.14M | -6.1812 |
Pyxis Oncology Inc Stock (PYXS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-03 | 재개 | Stifel | Buy |
| 2025-09-04 | 개시 | Guggenheim | Buy |
| 2024-11-21 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2024-11-08 | 개시 | Stephens | Overweight |
| 2024-08-08 | 개시 | Stifel | Buy |
| 2024-05-07 | 재개 | Jefferies | Buy |
| 2024-02-09 | 개시 | BTIG Research | Buy |
| 2024-01-23 | 개시 | Leerink Partners | Outperform |
| 2023-09-05 | 개시 | RBC Capital Mkts | Outperform |
| 2021-11-02 | 개시 | BofA Securities | Neutral |
| 2021-11-02 | 개시 | Credit Suisse | Outperform |
| 2021-11-02 | 개시 | Jefferies | Buy |
모두보기
Pyxis Oncology Inc 주식(PYXS)의 최신 뉴스
Is Pyxis Oncology Inc. stock recession proofHead and Shoulders Patterns & Create Your Free Watchlist Instantly - ulpravda.ru
Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
Goosehead Insurance Inc 2OX Stock Analysis and ForecastMomentum Trading Signals & Exceptional Return Capital - earlytimes.in
Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Is Pyxis Oncology Inc. stock positioned well for digital economyShort-Term Trading Alerts & Easy Tools to Analyze Your Investment Risk - bollywoodhelpline.com
Pyxis Oncology Inc. (PYXS) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Short Interest in Pyxis Oncology, Inc. (NASDAQ:PYXS) Drops By 57.3% - MarketBeat
Pyxis Oncology Stock Plunge: A Buy Signal? - StocksToTrade
Pyxis Oncology Stock Slides 73% With A 7-Day Losing Spree - Trefis
Will Pyxis Oncology Inc. stock benefit from automationEarnings Recap Summary & Weekly Setup with ROI Potential - Улправда
Bear Alert: Is Pyxis Oncology Inc. stock a contrarian buy2025 Year in Review & Safe Entry Momentum Stock Tips - Улправда
How Pyxis Oncology Inc. stock compares to growth peersQuarterly Profit Summary & Weekly High Conviction Trade Ideas - Улправда
Pyxis Oncology (NASDAQ:PYXS) Lowered to Sell Rating by Wall Street Zen - Defense World
Pyxis Oncology Stock 6-Day Losing Spree: Stock Falls 71% - Trefis
HC Wainwright & Co. Maintains Pyxis Oncology (PYXS) Buy Recommendation - Nasdaq
RBC Capital Maintains Pyxis Oncology (PYXS) Outperform Recommendation - Nasdaq
Pyxis Oncology sees cash runway into 4Q26 - MSN
Is Pyxis Oncology Inc. stock a dividend growth opportunity2025 Bull vs Bear & Long-Term Safe Return Strategies - DonanımHaber
Pyxis Oncology stock price target raised to $7 by H.C. Wainwright - Investing.com Nigeria
RBC Capital Lowers Price Target for Pyxis Oncology (PYXS) to $5, Maintains Outperform Rating | PYXS Stock News - GuruFocus
Analysts Sound Alarm On Pyxis Oncology's Tiny Trial - Benzinga
RBC Cuts Price Target on Pyxis Oncology to $5 From $8, Keeps Outperform, Speculative Risk - marketscreener.com
Pyxis plummets following phase 1 data on candidate for head and neck cancer - MSN
Is Pyxis Oncology Inc. stock a contrarian buy2025 Trade Ideas & Risk Adjusted Buy/Sell Alerts - Улправда
Pyxis Oncology Sees Unusually High Options Volume (NASDAQ:PYXS) - Defense World
Pyxis Oncology reports positive data for head and neck cancer drug By Investing.com - Investing.com South Africa
Fed Meeting: Is Pyxis Oncology Inc. stock positioned well for digital economyMarket Trend Report & AI Enhanced Trade Execution Alerts - Улправда
Pyxis Oncology stock falls as RBC cuts price target on complex trial data - Investing.com Australia
Pyxis Oncology stock falls as RBC cuts price target on complex trial data By Investing.com - Investing.com South Africa
Pyxis Oncology reports positive data for head and neck cancer drug - Investing.com Nigeria
Pyxis Oncology Stock (PYXS) Opinions on Phase 1 Cancer Drug Data - Quiver Quantitative
Stock Traders Buy Large Volume of Pyxis Oncology Put Options (NASDAQ:PYXS) - MarketBeat
Pyxis Oncology, Inc. (PYXS) Discusses Preliminary Phase 1 Data for MICVO in Recurrent and Metastatic Head and Neck Squamous Cell CarcinomaSlideshow (NASDAQ:PYXS) 2025-12-18 - Seeking Alpha
Transcript : Pyxis Oncology, Inc.Special Call - marketscreener.com
Pyxis Oncology stock plummets after early-stage cancer drug data By Investing.com - Investing.com South Africa
Pyxis Oncology stock plummets after early-stage cancer drug data - Investing.com
Pyxis Oncology’s Stock Moves: Time for Investors to Act? - timothysykes.com
PYXS: MICVO shows strong efficacy and safety in R/M HNSCC, both as monotherapy and with KEYTRUDA - TradingView — Track All Markets
Pyxis Oncology Reports Strong MICVO Data and Financing - TipRanks
Pyxis Oncology, Inc. Announces Positive Preliminary Phase 1 Data for MICVO - TradingView — Track All Markets
PYXS FinancialsIncome Statement - Quiver Quantitative
Pyxis Oncology (PYXS) shows promising MICVO results and extends cash runway - Stock Titan
Pyxis Oncology Inc (PYXS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
28.63%
자본화:
|
볼륨(24시간):